Forget CRISPR Therapeutics: This Gene?Editing Player Already Boasts the Profits It Dreams Of
2026-03-04 13:43:00 ET
Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously considered untreatable. That's why biotechs that specialize in gene editing and that succeed in making important breakthroughs could make investors who get in on the ground floor much richer over the long run.
One of the more famous companies in this niche is CRISPR Therapeutics (NASDAQ: CRSP) . Is this mid-cap company worth considering for investors looking to cash in on gene editing? It depends. For those who are risk-averse, there are arguably many better options out there, one of which is Vertex Pharmaceuticals (NASDAQ: VRTX) .
Let me explain.
NASDAQ: CRSP
CRSP Trading
4.99% G/L:
$58 Last:
525,701 Volume:
$55.59 Open:
